Overview

Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Tinzaparin may stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects of tinzaparin and to see how well it works in treating patients with metastatic kidney cancer that cannot be removed by surgery.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Vermont
Collaborator:
National Cancer Institute (NCI)
Treatments:
Dalteparin
Heparin, Low-Molecular-Weight
Tinzaparin